These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 657108

  • 21. Hypotension and disseminated intravascular coagulation following intralesional bacillus Calmette-Guérin therapy for locally metastatic melanoma.
    Cohen MH, Elin RJ, Cohen BJ.
    Cancer Immunol Immunother; 1991; 32(5):315-24. PubMed ID: 1998973
    [Abstract] [Full Text] [Related]

  • 22. Intralesional BCG, intravenous immune lymphocytes, and immunization with neuraminidase-treated tumor cells to manage melanoma; A clinical assessment.
    Seigler HF, Shingleton WW, Pickrell KL.
    Plast Reconstr Surg; 1975 Mar; 55(3):294-8. PubMed ID: 1118487
    [Abstract] [Full Text] [Related]

  • 23. Re-inventing intratumoral immunotherapy for melanoma.
    Triozzi PL, Tuthill RJ, Borden E.
    Immunotherapy; 2011 May; 3(5):653-71. PubMed ID: 21554094
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Regression of pulmonary metastatic disease associated with intralesional BCG therapy of intracutaneous melanoma metastases.
    Mastrangelo MJ, Bellet RE, Berkelhammer J, Clark WH.
    Cancer; 1975 Oct; 36(4):1305-8. PubMed ID: 1175129
    [Abstract] [Full Text] [Related]

  • 26. Immunologic defects in melanoma patients: lack of effect of BCG therapy.
    Gersten MJ, Hadden EM, Kaplan MH, Pinsky CM, Armstrong D, Hadden JW.
    Clin Bull; 1977 Oct; 7(2):63-9. PubMed ID: 902403
    [No Abstract] [Full Text] [Related]

  • 27. Mumps virus and BCG vaccine in metastatic melanoma.
    Minton JP.
    Arch Surg; 1973 Apr; 106(4):503-6. PubMed ID: 4572347
    [No Abstract] [Full Text] [Related]

  • 28. Immunotherapy of melanoma with BCG: two fatalities following intralesional injection.
    McKhann CF, Hendrickson CG, Spitler LE, Gunnarsson A, Banerjee D, Nelson WR.
    Cancer; 1975 Feb; 35(2):514-20. PubMed ID: 234291
    [Abstract] [Full Text] [Related]

  • 29. The effect of methanol extraction residue of BCG on the cellular immune response in patients with malignant melanoma.
    Bartal A, Cohen Y, Mekori T, Haasz R, Robinson E.
    Med Pediatr Oncol; 1979 Feb; 6(1):1-10. PubMed ID: 440203
    [Abstract] [Full Text] [Related]

  • 30. Adjuvant immunostimulation in malignant melanoma with oral Bacille Calmette-Guérin.
    MacGregor AB, Falk RE, Landi S, Ambus U, Samuel ES, Langer B.
    Can J Surg; 1977 Jan; 20(1):25-30. PubMed ID: 832200
    [Abstract] [Full Text] [Related]

  • 31. DNCB reactivity and prognosis in 419 patients with malignant melanoma.
    Camacho ES, Pinsky CM, Braun DW, Golbey RB, Fortner JG, Wanebo HJ, Oettgen HF.
    Cancer; 1981 May 15; 47(10):2446-50. PubMed ID: 7272900
    [Abstract] [Full Text] [Related]

  • 32. Influence of preexisting tumor immunity on Bacillus Calmette-Guérin immunotherapy of guinea pigs with both regional and disseminated tumor.
    Jessup JM, Riggs CW, Hanna MG.
    Cancer Res; 1977 Aug 15; 37(8 Pt 1):2565-73. PubMed ID: 872084
    [No Abstract] [Full Text] [Related]

  • 33. Recurrent malignant melanoma: effect of adjuvant immunotherapy on survival.
    McCulloch PB, Dent PB, Blajchman M, Muirhead WM, Price RA.
    Can Med Assoc J; 1977 Jul 09; 117(1):33-6. PubMed ID: 861909
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.